Statement on the Passing of Senator Coburn

WASHINGTON, D.C., DISTRICT OF COLUMBIA, UNITED STATES, March 30, 2020 /EINPresswire.com/ — FOR IMMEDIATE RELEASE
CONTACT: Anne Di Gregory
March 30, 2020 communications@menshealthnetwork.org
(202) 543-6461 ext. 101

Statement on the Passing of Senator Tom Coburn

WASHINGTON – Men’s Health Network (MHN) wishes to acknowledge with sadness the recent passing of Senator Tom Coburn (R-Oklahoma) following a long and brave battle with cancer. Sen. Coburn, during his long and accomplished tenure representing the Great State of Oklahoma in the U.S. House of Representatives and the U.S. Senate, distinguished himself as a strong proponent of fiscal responsibility.

As a physician, he also was eloquent, tireless and effective in his efforts and advocacy to ensure that patients received the health care they needed, and deserved.

"Senator Coburn's skill and dedication will be missed by all Americans, particularly by his fellow healthcare professionals. The boys, men, and families of America have lost a strong advocate," said Dr. Salvatore J. Giorgianni, Jr., Senior Science Advisor, Men's Health Network.

On behalf of MHN’s staff, volunteers, and advisors we pass along our thanks to this wonderful American Statesman as well as our sincere and heartfelt condolences to his family and loved ones.

Men's Health Network

Men's Health Network (MHN) is an international non-profit organization whose mission is to reach men, boys, and their families where they live, work, play, and pray with health awareness messages and tools, screening programs, educational materials, advocacy opportunities, and patient navigation. Learn more about MHN at www.MensHealthNetwork.org and follow them on Twitter @MensHlthNetwork and Facebook at www.facebook.com/menshealthnetwork . For more information on MHN's ongoing Dialogue on Men's Health series, visit www.DialogueOnMensHealth.com

Anne Di Gregory
Men's Health Network
+ +1 703-635-9416
email us here
Visit us on social media:
Facebook
Twitter
LinkedIn


Source: EIN Presswire

IntuitiveX, WSMA, & US China Innovation Alliance Host COVID-19 Technology Innovation Summit

IntuitiveX, Washington State Medical Association, and US China Innovation Alliance bring together thousands of people for COVID-19 Technology Innovation Summit

SEATTLE, WASHINGTON, UNITED STATES, March 29, 2020 /EINPresswire.com/ — IntuitiveX, Washington State Medical Association, and US China Innovation Alliance are bringing together thousands of interested life science innovators, professionals, physicians, entrepreneurs, and investors together to attend the COVID-19 Technology Innovation Summit.

The purpose of the event is to bring together a global audience to discuss the recent innovations tackling the COVID-19 pandemic while providing an update on the current COVID-19 outbreak.

“As the epicenter of the COVID-19 outbreak in the U.S., Seattle, Washington serves as ground zero for this unprecedented national healthcare crisis. IntuitiveX, Washington State Medical Association, and U.S. China Innovation Alliance are partnering to host the first online COVID-19 Technology Innovation Summit to help facilitate the most up-to-date information from experts on the front lines and to feature innovative companies developing cutting-edge solutions to help combat this global pandemic.” Dr. Jeffrey Roh, CEO of IntuitiveX.

We will be joined by experts from the Center for Disease Control and Prevention (CDC), Washington State's Department of Health, the City of Seattle, Microsoft Healthcare, and early-stage COVID-19-related startups in an effort to share the innovative ways that Washington State—the epicenter of the U.S. viral outbreak—is taking action to solve COVID-19, one patient at a time.

For-profit companies ranging from startups to established multinational corporations and public health agencies ranging from local, regional, state and federal governments will be providing unique insights into how they are tackling the problem within their organizations and paving the way for innovative thinking to tackle the problems within their communities.

"No one would argue that today, we live in highly uncertain and historically unprecedented times. The worldwide effects of the COVID-19 global pandemic have permanently changed our lives forever. But it’s through challenging moments like these that we, as a society, are faced with a choice to either act passively and do nothing, or actively rally together to overcome the most critical healthcare crisis that our generation has faced in our lifetime." Dr. Jeffrey Roh, CEO of IntuitiveX.

The Agenda

4:00 PM: Global Healthcare Implications of the COVID-19 Pandemic — Jeff Roh, CEO of IntuitiveX
4:05 PM: COVID-19 Impact on U.S. Economy — Jun Hong, CFO & Strategist of IntuitiveX
4:10 PM: Q&A Panel

Public Health Agency Perspective

4:20 PM: Center for Disease Control & Prevention (CDC) — Diana Yassanye, Public-Private Partnerships
4:25 PM: Washington State Department of Health — Lacy Fehrenbach, MPH, CPH, Assistant Secretary, Prevention and Community Health
4:30 PM: King County — Executive Dow Constantine
4:35 PM: City of Seattle — Micheal Fong, Deputy Mayor of Seattle
4:40 PM: Evergreen Health (location of the first reported case of COVID-19 in Washington) — Ettore Palazzo, CMO of Evergreen Health
4:45 PM: Q&A Panel

Corporation Perspective

4:55 PM: Microsoft Healthcare — Desney Tan, Managing Director of Microsoft Healthcare & Chief Technologist at IntuitiveX
5:00 PM: Outdoor Research — Jason Duncan, VP of Tactical & Innovation of Outdoor Research
5:05 PM: Swedish Hospital — Jason Goldman, MD, MPH, Infectious Diseases, Swedish Hospital
5:10 PM: Q&A Panel

Startup Innovators

5:20 PM: Transpara Health — Susie Kataoka, CEO
5:25 PM: Arc Health — Nirav Shah and Ajay Gupta, Co-Founders
5:30 PM: Kinaptic — Joseph Curcio, COO
5:35 PM: Redoxagen — Craig Fryar, President & CEO, Torquin, LLC
5:40 PM: Pinpoint Sciences — Lisa Diamond, CEO
5:45 PM: Q&A Panel

5:55 PM: Closing Remarks & Announcements — Jeff Roh, CEO of IntuitiveX

The online, virtual summit will be held via a zoom conference – https://zoom.us/j/501381863 , and will be organized by IntuitiveX, Washington State Medical Association (WSMA), and the US China Innovation Alliance.

About: IntuitiveX is a life science consulting firm and incubator. With a team comprised of life science entrepreneurs, investors, and innovators, they bring a combined 100+ years of experience in R&D, Clinical, Surgical, IP Strategy, Prototyping, Product Development, and Commercialization. They catalyze medical innovation by removing the complexities, cost barriers, and time sensitivities related to introducing new products into the market. From initial concept to final commercialization, IntuitiveX has the in-house knowledge and network to meet the unique needs of the most innovative life science companies in the world. We’ve currently incubated more than 12+ portfolio companies and are always in search of more.

Website: www.intuitive-x.com

Tickets to the COVID-19 Technology Innovation Summit can be redeemed here: https://www.eventbrite.com/e/covid-19-technology-innovation-summit-tickets-101001269516

Emeka Alozie
IntuitiveX
+1 281-902-6391
email us here


Source: EIN Presswire

Prefabricated Modular Steel Panel Hospital Intensive Care Units (ICU's)

Intensive Care Units (ICU’s)

ICU Front View

Isolation Room with Negative Pressure HEPA Filtration & UV Light

Prefabricated Modular Steel Panel Hospital Intensive Care Units (ICU's) & Modular Isolation Rooms & Negative Pressure Rooms with HEPA Filter & UV Light Options

We have 330 million persons in the USA. In 12-18 months, 1% of the population (if tested) may be infected with COVID-19. If proper protocol is followed, millions of isolation units may be needed.””

— M.R. Secure Sales LLC Spokeman

MANALAPAN, NEW JERSEY, UNITED STATES, March 29, 2020 /EINPresswire.com/ — Panel Built has introduced Prefabricated Modular Steel Panel Hospital Intensive Care Units (ICU's) and Prefabricated Modular Hospital Isolation Rooms along with Negative Pressure Rooms, to help hospitals due to room shortages caused by the COVID-19 surge. Steel panel rooms have multiple uses and can be customized and adapted for for the individual hospital needs.
Panel Built, modular construction provider for 25 years, now offers a way for medical facilities to create and expand their infectious patient isolation areas with modular Isolation rooms. With the growing Coronavirus pandemic spreading across the United States and internationally, Panel Built’s modular isolation rooms are a convenient solution for hospitals that need to increase their single-occupancy, isolation space as quickly as possible. Using a panelized wall system, the isolation rooms are fully fabricated in Panel Built’s modular construction facilities. The components are then delivered and assembled on site. This design allows for prefabricated, quickly assembled isolation rooms that have fully customized layouts and designs.

Panel Built’s ICU's and isolation rooms offer options, (where situations warrant), for HVAC systems with fan filter units (FFUs) to keep the room at appropriate temperatures and constantly filter particles with HEPA filtration and UV light from the environment’s air supply with the numerous air exchanges per hour. Patient isolation rooms can be customized with a negative pressure environment for patients who may have an impaired immune system and may be a carrier for other infectious diseases that are airborne spread along with the droplet Coronavirus. Diseases such as TB, Measles, Mumps, Varicella and other respiratory infections fall into the airborne category. When the negative pressure isolation room is needed, the air pressure inside the isolation room is lower than entrance ante room to keep air flowing into the patient isolation room instead of out, keeping any contaminants or particles from escaping the room. All isolation rooms should be used in conjunction with proper staff and equipment sanitizing and hospital contamination control procedures.

Panel Built’s Steve Grzesik, Sales Manager Welded Steel Division, stated, "While Panel Built is a for-profit company, our first objective is to help our nation and others meet the challenge and help save lives. Our nation's largest hospitals and long term care centers will need all the isolation bed space they can get, and Panel Built is ready to help meet the need."

M.R. Secure Sales LLC spokesman stated the following, " There are 330 million persons in the USA. Predictions are, over the next 12-18 months, approximately 1% of the USA population (if tested) may be infected with the Coronavirus. If proper protocol is to be followed, millions of isolation rooms may be needed in the USA alone. The nations largest hospitals in total, may have fewer than several thousand isolation rooms. "
Panel Built was founded in 1995 by brothers Pat and Mike Kiernan, and began with the construction of pre-manufactured buildings. Today, Panel Built offers a complete line of custom modular offices, mezzanines, security booths, pre-assembled exterior buildings, and cleanrooms. Panel Built isolation rooms are designed 100% to customer specification and are delivered with components ready for installation. Panel Built’s main mission is, “Solving Our Customers’ Space Needs with Excellence and Great Customer Service.”

Isolation Room Brochure: https://www.panelbuilt.com/wp-content/uploads/Isolation-Rooms.pdf

For more information, visit: https://www.panelbuilt.com/isolation-rooms/

www.panelbuilt.com

The New Generation in Modular Buildings, Enclosures & Mezzanines

Contact information:

Mike Rosenberg
M.R. Secure Sales
Limited Liability Company
Cell 732-491-5120
mrosenberg@mrsecuresales.co

Steve Grzesik
Sales Manager Welded Steel Division,

Panel Built, Inc.
P.O. Box 2658, Blairsville, GA 30514
Office (706) 745-6540 TF (800) 636-3873 Fax (706) 745-1450

“M.R. Secure Sales LLC represents leaders in Modular Prefabricated Modular Steel Panel Hospital Intensive Care Units (ICU's) Isolation rooms and Negative Pressure Infectious Disease Isolation Rooms,Clean Rooms,Guard/Security/Parking Booths & Bus Shelters, Offsite Sustainable Construction of Steel and Concrete Multi-Story Modular Schools, Dorms, Condos, Town Houses, Senior Housing, Hotels, Retail Stores, Emergency Care Facilities, Equipment/Telecommunication Shelters, Modular Correctional Facilities, Modular Steel Police/Jail and Prison Cells,Modular Offices within in Factories and Warehouses, and Miscellaneous Metals and Custom Steel Railings and Stairs”

MIKE ROSENBERG
+1 732-491-5120
email us at mrosenberg@mrsecuresales.com
Visit us on social media:
Facebook
Twitter
LinkedIn
Michael J Rosenberg
M.R. SECURE SALES LLC
+1 732-491-5120

Michael J Rosenberg
M.R. SECURE SALES LLC
+1 732-491-5120
email us here
Visit us on social media:
Twitter


Source: EIN Presswire

Vitro Biopharma First Quarter ended January 31st 2020 Financial Results of Operations

Vitro Biopharma is pleased to announce a record 1st comparative quarter in Total Revenues of $225,921 vs $192,895 an increase of 17% versus last year.

Vitro Diagnostics Inc. (OTCMKTS:VODG)

Vitro is pleased to have recently been recognized by Bioinformant as "a Company Tracking the Coronavirus".
https://bioinformant.com/product/coronavirus-covid-19-report/”

— Dr. James Musick

GOLDEN, CO, USA, March 28, 2020 /EINPresswire.com/ — Vitro Biopharma First Quarter ended January 31st 2020 Financial Results of Operations

Golden, Colorado-March 26, 2020-Vitro Diagnostics, Inc. (OTCPK: VODG), dba Vitro Biopharma, announced its 1st quarter ended January 31st, 2020 financial results of operations.

Vitro Diagnostics Inc. (“Vitro Biopharma”) is pleased to announce a record 1st comparative quarter in Total Revenues. Vitro Biopharma recorded 1st quarter revenues of $225,921 vs $192,895 an increase of 17% over the same comparative quarter last year. In addition, Stem Cell treatments accounted for 74% of the revenues up from 71% of the revenues in the prior comparative quarter last year. Current quarter stem cell revenues were $167,750 for the 1st quarter ended January 31, 2020 vs $137,123 for the first quarter ended January 31, 2019.

The company’s gross profit margins improved to 75% up from 73% in the comparative prior year’s quarter. Gross margin improvement is in line with the strategic direction of the company to expand the market of its flagship product AlloRx™ Stem Cells. The company’s clean-room lab expansion last year and expanded Stem Cell manufacturing using its patent-pending cell line, has increased efficiencies and lowered production costs.

Overall operating expenses increased in the quarter to $193,385 from $147,398 in the prior year’s comparative quarter. The increase in expenses reflects additional investment as the Company expands its capability to service its strategic direction of offshore Stem Cell treatments while also expanding into US markets. The company expended additional resources on external consultants supporting our regulatory status in maintaining ISO9001 & ISO13485 certifications, expanding our efforts to approach US markets through FDA filings and advancement of existing patent filings.

The company’s first quarter is its most seasonal quarter as the period between Thanksgiving and the New Year is slow for all the company’s revenue lines of Nutra Vivo™/STEMulize, AlloRx™ Stem Cells, private labeled InfiniVive MD™ Stem Cell Serum and our core research products.

During the quarter the company achieved and pursed the following company objectives

• Series A Convertible Preferred Stock Offering:

During the quarter the company commenced a Series A Convertible Preferred Stock offering to accredited investors under the SEC Regulation D exemption. The preferred Stock is priced at $25 per share which is convertible at $0.25 cents per share for a total of 100 shares. The minimum investment is $50,000 per unit. The company sold $450,000 of the Series A Convertible Preferred Stock during the quarter. The company has additional interest in the offering and subsequent to the quarter has sold an additional $50,000 unit for a total to date of $500,000. The company has additional interested parties for approximately $200,000. The offering is for a total of $1,000,000.

• Expansion of revenues & results from the clinical trials in the Cayman Islands:

Our partnership with DVCStem in the Cayman Islands continued to advance through treatment of new & previous patients. This IRB-approved protocol targets patients with inflammatory conditions including multiple sclerosis, systemic inflammation and new indications including Crohn's disease, Alzheimer’s disease and COPD. To date we have treated 60 patients including repeat treatments. There have been no serious adverse events and we continue to gain evidence of efficacy. One of the initial MS patients has now received a second transplant of our AlloRx™ Stem Cells and he has reported significant therapeutic benefits of both the initial and subsequent therapy. He had received an earlier transplant of adipose-derived MSCs that was effective, but the improvement lasted 3 months while AlloRx™ Stem Cell therapy lasted 18 months. We had predicted such a clinical outcome based on significantly higher potency of umbilical cord MSCS compared to those derived from adipose tissue or bone marrow. The Crohn’s disease patient showed significant improvement as did both the AD & COPD patients.

• Further Expansion into US Markets-FDA IND:

The strategic development of our stem cell therapies involves pursuit of both offshore and domestic markets. The partnership with DVC Stem, our IRB-approved trial in the Bahamas together with other strategic opportunities represent offshore operations & prospects. During Q1 2020, we initiated expansion into US therapeutic markets through development of an Investigational New Drug (IND) application for submission to FDA. Once approved, an IND allows the conduct of clinical trials for specific medical conditions in the US.

Given the current COVID-19 pandemic, our initial IND application is for use of AlloRx™ Stem Cells in treatment of Coronavirus infections. This is supported by clinical studies showing that 17 critically ill patients responded favorably to IV infusion of umbilical cord-derived MSCs. All patients were receiving assisted ventilation but 3 days following stem cell therapy, were removed from ventilators and subsequently discharged from the hospital. We are pursuing discussions with FDA to establish the appropriate regulatory pathway and expedited review options given the current emergency circumstances. (See Subsequent Events, below, for additional discussion of our COVID-19 response.) Once our initial IND is in place, we have plans for additional INDs for stem cell therapy of musculoskeletal conditions and Alzheimer’s disease.

• PR Medica Opportunity:

We have received an initial order of AlloRx™ Stem Cells for testing purposes by PR Medica located in Cabo San Lucas. Given successful test results, we anticipate subsequent new revenue generation from this customer.

• InfiniVive MD™ Stem Cell Serum:

Vitro Biopharma’s cosmetic topical stem cell serum is being distributed by InfiniVive MD™ into cosmetic clinics that are providing the topical treatment as a beautification product. To date the company’s product is being offered in 10 cosmetic clinics.

Our partner, Dr Jack Zamora, MD was a keynote speaker at a master session at the American Academy of Cosmetic Surgery annual meeting in late February. The topic of his presentation was “Topical Stem Cells, Exosomes and Conditioned Media Serums in Aesthetics.” This was the official launch of the InfiniVive-MD platform including: Dailey Serum, Stem Cell Serum 2.0 & Exosomes within the product line. Vitro Biopharma will manufacture & private label these new products for distribution in the US. We anticipate InfiniVive MD growth, development and revenues to mirror the development of Apyx subdermal plasma skin tightening as a cosmetic treatment and technique that has gone global.

www.jackzamoramd.com www.infinivivemd.com

• Research and Development, Facility Expansion & Patent Prosecution

Our core research product sales continued to expand in Q1 2020. Our facility expansion continued with addition of manufacturing capacity and development of plans to add operational facility to increase outputs further by 100% or more. We were also in discussions with the USPTO regarding our pending patents for our novel stem cell therapy and stem cell activation technology. We continue to work closely with our examiner and have established communication channels to facilitate awards of these patents.

• SUBSEQUENT EVENTS: COVID-19 Opportunity and Risks

The COVD-19 pandemic is a significant obstacle for all business. However, Vitro Biopharma is uniquely positioned since we have a potential effective therapy. This is based on 3 independent reports showing efficacy of stem cell therapy in 17 COVID-19 patients. All were treated with IV umbilical cord MSCs comparable to AlloRx™ Stem Cells and all 17 required respiratory assistance but within 3-4 days of treatment, were able to breath without ventilators and were discharged within 14 days. https://www.scmp.com/news/china/society/article/3053080/coronavirus-critically-ill-chinese-patient-saved-stem-cell On the contrary, untreated patients on ventilators have death rates of 50% or more. We have received a formal request to supply AlloRx™ Stem Cells for compassionate use from a major university medical center and several other potential clinical partners have also expressed interest in using our cells to treat COVID-19 patients. We are presently working with the FDA to gain authority to begin clinical testing in the US. We are currently assessing the overall financial impact of the COVID-19 pandemic on our business, but this depends on overall control of the pandemic. There have been no staff layoffs and our workers are considered essential since we conduct essential research to the COVID-19 response.

Dr. Jim Musick, CEO of Vitro Biopharma, said, “We are very pleased with the increased revenue growth during our first quarter 2020 compared to the prior year However all our resources are currently focused on the emergency response to the COVID-19 pandemic and increasing our inventory of AlloRx to satisfy anticipated emergency demand to treat critically ill COVID-19 patients.” The Company is working to get expedited clinical trial approvals to sell our AlloRx Stem Cells to hospitals coping with the pandemic. Vitro is pleased to have recently been recognized by Bioinformant as "a Company Tracking the Coronavirus".
https://bioinformant.com/product/coronavirus-covid-19-report/ We anticipate clinical progress in the effectiveness of our stem cell therapies while expecting to see a reduction in our offshore and cosmetic revenues for the next quarter or two. The company is in a good cash position to weather this storm and simultaneously advance its AlloRx stem cell therapies into clinical trials.

In summary, Vitro Biopharma is advancing as a key player in regenerative medicine with 10+years’ experience in the development and commercialization of stem cell products for research, recognized by a Best in Practice Technology Innovation Leadership award for Stem Cell Tools and Technology and a growing track record of successful translation to therapy. We are leveraging our proprietary technology platform to the establishment of international Stem Cell Centers of Excellence and regulatory approvals in the US and worldwide.

Sincerely yours,

James R. Musick, PhD.
President, CEO & Chairman of the Board
www.vitrobiopharma.com

Forward-Looking Statements

Statements herein regarding financial performance have not yet been reported to the SEC nor reviewed by the Company’s auditors. Certain statements contained herein and subsequent statements made by and on behalf of the Company, whether oral or written may contain “forward-looking statements”. Such forward looking statements are identified by words such as “intends,” “anticipates,” “believes,” “expects” and “hopes” and include, without limitation, statements regarding the Company’s plan of business operations, product research and development activities, potential contractual arrangements, receipt of working capital, anticipated revenues and related expenditures. Factors that could cause actual results to differ materially include, among others, acceptability of the Company’s products in the market place, general economic conditions, receipt of additional working capital, the overall state of the biotechnology industry and other factors set forth in the Company’s filings with the Securities and Exchange Commission. Most of these factors are outside the control of the Company. Investors are cautioned not to put undue reliance on forward-looking statements. Except as otherwise required by applicable securities statutes or regulations, the Company disclaims any intent or obligation to update publicly these forward-looking statements, whether as a result of new information, future events or otherwise.

CONTACT:
Dr. James Musick
Chief Executive Officer
Vitro BioPharma
(303) 999-2130 Ext. 3
E-mail: jim@vitrobiopharma.com

Source: Vitro Diagnostics, Inc.

www.vitrobiopharma.com

https://vitrobiopharma.com/first-quarter-2020-financial-results-of-operations/

John Evans
Vitro BioPharma
+1 303-601-7855
email us here


Source: EIN Presswire

Renowned Lawyer Jay Sekulow Teams Up with John Schneider for Exclusive Performance of ’The Dukes of Hazzard’ Theme

Jay Sekulow Band featuring John Schneider and Trick Pony’s Keith Burns, “Theme from ‘The Dukes of Hazzard’ (Good Ol’ Boys)”

John Schneider and Jay Sekulow

Days after leading President Trump’s defense team to an impeachment acquittal, Sekulow and his all-star band joined John Schneider for an exclusive performance.

We hope you enjoy this exclusive performance of 'The Dukes of Hazzard’ theme song with Bo Duke himself.”

— Jay Sekulow

NASHVILLE, TN, USA, March 27, 2020 /EINPresswire.com/ — In late February, days after leading President Donald J. Trump’s defense team to a victorious impeachment acquittal, Jay Sekulow was behind his drum kit leading his all-star band through rehearsals at his Nashville production facility. The following day, they would be joined by legendary actor and chart-topping recording artist John Schneider and special guest Keith Burns of Trick Pony, for an exclusive live performance of "Theme from 'The Dukes of Hazzard' (Good Ol' Boys)."

Released on Facebook Thursday evening, the video received over 100,000 in the first two hours, and it continues to gain traction. Watch the exclusive performance here: https://www.facebook.com/JaySekulow/videos/206218037328838/

“'Straightening the curves, flattening the hills' sounds very familiar these days as America practices social distancing,” says Sekulow. "With that in mind, we wanted to release a music video featuring special guests John Schneider and Keith Burns from Trick Pony. We hope you enjoy this exclusive performance of 'The Dukes of Hazzard’ theme song with Bo Duke himself. And we'll will have more videos featuring John and Keith coming soon."

"I had a blast with Jay and the gang," says Schneider. "Not only is Jay a crackerjack attorney, but he’s one heck of a musician too!"

When he’s not arguing cases at the Supreme Court of the United States, testifying before Congress, or serving as the personal attorney of President Donald J. Trump, Jay Sekulow can be found behind his drum set or playing guitar leading the Jay Sekulow Band. What started as a hobby has turned into a stellar lineup with an all-star cast, featuring former members of Kansas, Petra, DC Talk, and more. Over the past few years, the Jay Sekulow Band has performed with legendary guests such as Ricky Skaggs and Lee Greenwood, and their music videos have been streamed by millions online. The band is known for their unmatched covers of classic hits as well as original songs such as "Hope of Jerusalem" and "Undemocratic."

ABOUT JOHN SCHNEIDER: John’s extensive acting career includes the iconic roles of "Bo Duke" on The Dukes of Hazzard, “Jonathan Kent” on Smallville and "Jim Cryer" on his current series, Tyler Perry's The Haves and the Have Nots (now in Season 7). John was also a fan favorite on Dancing with the Stars in 2018. In addition to his incredible acting career, John has over 20 albums to his credit and four #1 singles on the Billboard Country chart. It’s also worth noting that John co-founded (with Marie Osmond) the Children's Miracle Network. For more info, visit https://johnschneiderstudios.com.

ABOUT JAY SEKULOW: Jay Sekulow is Chief Counsel of the American Center for Law and Justice (ACLJ), one of the most prestigious law firms in the country. He is an accomplished Supreme Court advocate, renowned expert on religious liberty, a #1 New York Times-bestselling author, and a respected broadcaster.

Brian Mayes
Nashville Publicity Group
+1 615-417-8149
email us here

Jay Sekulow Band featuring John Schneider and Keith Burns, “Theme from ‘The Dukes of Hazzard’ (Good Ol’ Boys)”


Source: EIN Presswire

A 3-Step Plan to Save Lives

Surgical gloves and mask and home-based blood test kit.

As John Norris explains, we urgently need three tools to defeat Covid-19.

When we tell the story of this time, let no one say that we gave nothing less than our best to save American lives.

BOSTON, MASSACHUSETTS, UNITED STATES, March 27, 2020 /EINPresswire.com/ — American ingenuity and determination are the key ingredients needed to win the battle against the coronavirus. With the greatest scientific minds in our midst, and the political will to execute on an ambitious plan, there is no reason we cannot defeat the virus in a matter of months.

The plan that I have devised requires the manufacture and distribution of three products and the commitment by a majority of Americans to their consistent use. With the support of the U.S. President and all 50 governors, this plan could easily help to save at least 50,000 American lives.

Not insignificantly, it could also help restore our economy.

American lives – young or old, disabled or immunocompromised, or the picture of health – are not expendable. They are not to be accepted as “collateral damage.” When we tell the story of this time, let no one say that we gave nothing less than our very best to save American lives.

I have spent my professional life in the service of public health, having previously served as the Principal Deputy Commissioner of the U.S. Food and Drug Administration and as a health policies and management faculty member at Harvard. I now serve as Executive Chairman of FDTH Regulatory Affairs Strategies, which provides healthcare strategic advisory services worldwide.

The coronavirus is a global public health challenge unlike any we have faced in decades. Like most unfathomably difficult projects, it must be broken down into smaller, manageable steps.

The recommendations described below would be in addition to the current precautions we are already taking:
• Regular, thorough hand-washing
• Disinfection of frequently used surfaces
• In-home quarantine or, if needed, hospitalization of the infected

I also recommend the deployment of three additional tools.

1. SURGICAL GRADE BUT LESS COMPLEX GLOVES
If even half of all Americans wore highly protective gloves whenever outside their home, the “touching-transfer” of the disease, both direct and indirect, would be cut significantly.

Produced in the tens of millions, the cost of these gloves would dramatically be reduced. Each household would need one pair per person, per month. Let’s start with three months but be prepared to extend it another three months.

2. SURGICAL-GRADE BUT LESS COMPLEX TWO-WAY MASKS
If half of all Americans also wore surgical-grade masks whenever outside their home, sneezing and coughing transfer, both direct and indirect, would be reduced.

Produced in the tens of millions, the cost of these masks would dramatically be reduced. Each household would need four masks per person per month, changing masks weekly. Assuming each person’s workplace is kept virus-free, the masks would only have to be worn when they are outside work or home.

3. IN-HOME, HIGH-SPEED CORONAVIRUS TESTS
The lack of testing capacity has been identified as our primary weakness in this battle, because we don't know who has it, but is either not sick yet or is just an asymptomatic carrier. The availability of an in-home, high-speed (from start to finish) test would be revolutionary.

It is safe to assume that the greatest scientific minds in our country are already working on bringing such a test to market. They will, of course, require expedited funding and government approval, but more than any other tool in our tool bag, a widely available, high-speed test would prevent the unwitting spread to others.

Initially, these tests should be monitored, via the Internet, by a healthcare professional. Once they are observed to be roughly as safe and effective as an in-home blood sugar tests used by diabetics, the tests could be fully self-administered, saving the healthcare delivery system billions.

SINE QUA NON
The plan I have outlined would require the consistent, committed use by every household who volunteers to take part. They would be asked to commit to themselves and their housemates to wearing the gloves and mask every time they leave their homes.

And, every time they return they would be asked to hang up their mask and gloves and test themselves, as well as others seeking entry to their home.

LOGISTICS
The number of households likely to be involved here is around 64 million of the 128 million households in America. Each of these typically house three residents. In other words, a total of 192 million Americans, or roughly 60% of our 330 million-person population.

For distribution, the U.S. Postal Service has the capacity to distribute 30-million packages per day. It will take only nine days to distribute all three items.

As soon as the initial steps are started, the more successful this plan will be. It is estimated that the lives of some 50,000 Americans (and perhaps another 100,000 worldwide) might be saved, if the products and the device are distributed by June 30th, a possible but difficult target date to meet.

COSTS
Those who say such a campaign would be prohibitively expensive should consider what the pandemic has already cost. We are already facing trillions of dollars in losses, and we have barely left the starting blocks. After calculating the likely full cost of not winning the war, soon, the real cost of doing less than we can do to win this war quickly is obscene.

The President is looking for a “Big” strategy to win this war. Hopefully, he will embrace this well-thought-through “three-legged strategic action plan” because it is likely to produce enormous benefits if it is fully employed as soon as possible.

Take a hard look, Mr. President. You, too, Governors of our 50 states. We will support you. We will have your backs. This aggressive plan might make all the difference. Nearly everyone, expert or not, agrees we need massive testing, now. This is a smart and inexpensive way to do it.
______________
The Hon. John Norris is an FDA Former Principal Deputy Commissioner, a Harvard Former Health Policy and Management Faculty Member, and Chairman of FDTH Regulatory Affairs Strategies, as well as an inventor-entrepreneur and frequent drug, device, Healthcare-IT, clinical lab, and hospital-system visionary, innovator, advisor, and board member. He can be reached at john.norris.jd.mba@fdthregulatoryaffairsstrategies.com.

John Norris
FDTH Regulatory Affairs Strategies
+1 617-680-3127
email us here


Source: EIN Presswire

Medical Animation Market 2020 Global Trend, Segmentation and Opportunities, Forecast 2026

Wiseguyreports.Com Adds “Medical Animation -Market Demand, Growth, Opportunities and Analysis Of Top Key Player Forecast To 2025” To Its Research Database

PUNE, MAHARASHTRA, INDIA, March 27, 2020 /EINPresswire.com/ — Medical Animation Industry

Description

Global Medical Animation Market is accounted for $130.47 million in 2016 and is expected to reach $421.11 million by 2023 growing at a CAGR of 18.2% during the forecast period. Growing penetration of Smartphones, rising usage of medical animation by life sciences & medical device and increasing ageing population are some of the factors fueling the market growth. However, high cost of medical animation services is hampering the market. Emerging economies are offering new growth opportunities for the players in the medical animation market.

Advent of biological illustration and 3D computer graphics in healthcare marketing is contributing towards the dominant share of life science segment. Increasing research activities for the development of new product and related awareness concerning to various injuries, diseases and defects, the adoption of animated studies is anticipated to increase in coming years. The Asia-Pacific region is expected to grow at the highest CAGR during the forecast period. The high growth of this region can be attributed to the growing pharmaceutical industry, growing number of medical institutes in India, lucrative medical devices industry in China, entry of local players and low cost of medical animation in India.

Some of the key players in Medical Animation market include

Infuse Medical, Hybrid Medical Animation, Inc., Ghost Productions, Inc., Scientific Animations, Inc., Invivo Communications, Inc., Random42 Scientific Communication, Radius Digital Science , Nucleus Medical Media, AXS Studio, Inc., Visible Body, Elara Systems, Inc., Animated Biomedical Productions, Xvivo Scientific Animation, Blausen Medical Communications, Inc., Understand.Com, Trinsic Animation, LLC., Viscira and Medmovie, Inc.

Request for Sample Report @ https://www.wiseguyreports.com/sample-request/2768994-medical-animation-global-market-outlook-2017-2023

Therapeutic Areas Covered:
• Oncology
• Cosmeceuticals/Plastic Surgery
• Dental
• Cardiology
• Other Therapeutic Areas
o Orthopedics
o Neurology
o Gastroenterology
o Ophthalmology
o Gynecology
o ENT

Animation Types Covered:
• 2D Animation
• 3D Animation
• Real Time Imaging (4D Animation)
• Flash Animation

End Users Covered:
• Hospitals, Surgical Centers, and Clinics
• Academic Institutes
• Life Science Companies
• Medical Device Manufacturers
• Other End Users

Applications Covered:
• Cellular and Molecular Studies
• Patient Education
• Drug Mechanism of Action (MOA) and Approval
• Surgical Training and Planning
• Other Applications

Leave a Query @ https://www.wiseguyreports.com/enquiry/2768994-medical-animation-global-market-outlook-2017-2023

Regions Covered:
• North America
o US
o Canada
o Mexico
• Europe
o Germany
o France
o Italy
o UK
o Spain
o Rest of Europe
• Asia Pacific
o Japan
o China
o India
o Australia
o New Zealand
o Rest of Asia Pacific
• South America
o Argentina
o Brazil
o Chile
o Rest of South America
• Middle East & Africa
o Saudi Arabia
o UAE
o Qatar
o South Africa
o Rest of Middle East & Africa

What our report offers:
– Market share assessments for the regional and country level segments
– Market share analysis of the top industry players
– Strategic recommendations for the new entrants
– Market forecasts for a minimum of 7 years of all the mentioned segments, sub segments and the regional markets
– Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
– Strategic recommendations in key business segments based on the market estimations
– Competitive landscaping mapping the key common trends
– Company profiling with detailed strategies, financials, and recent developments
– Supply chain trends mapping the latest technological advancements

Buy Now @ https://www.wiseguyreports.com/checkout?currency=one_user-USD&report_id=2768994

Continued…

Contact Us: Sales@Wiseguyreports.Com Ph: +1-646-845-9349 (Us) Ph: +44 208 133 9349 (Uk)

Norah Trent
wiseguyreports
646 845 9349 / +44 208 133 9349
email us here


Source: EIN Presswire

Xian Tourism Market 2020 Global Analysis, Opportunities And Forecast To 2026

Wiseguyreports.Com Adds “Xian Tourism -Market Demand, Growth, Opportunities and Analysis Of Top Key Player Forecast To 2025” To Its Research Database

PUNE, MAHARASHTRA, INDIA, March 27, 2020 /EINPresswire.com/ — Xian Tourism Industry

Description

This report focuses on the global Xian Tourism status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Xian Tourism development in United States, Europe and China.

Tour is a kind of leisure activity, meaning that people with families or friends go out to relax themselves and get out of the tedious work or maybe trouble things from life for the time being. Now with the society developing and people’s living standard improving, tour is more and more popular.

The National Outline for Tourism and Leisure (2013–2020), released in 2013 by the State Council,14 is expected to further boost domestic tourism by implementing a national system of paid holidays by the end of 2020. The government’s 12th Five-Year Plan, which aims to increase living standards, should also contribute to this development.

In 2017, the global Xian Tourism market size was 20300 million US$ and it is expected to reach 46700 million US$ by the end of 2025, with a CAGR of 11.0% during 2018-2025.

The key players covered in this study

Citadines Centra
Mercure Xi’an on Renmin Square
Chenggong International Hotel
Hilton Xi’an
The Westin Xi’an
Sofitel Xi’an on Renmin Square
Golden Flower Hotel
Grand Park Xi’an

Request for Sample Report @ https://www.wiseguyreports.com/sample-request/3431850-global-xian-tourism-market-size-status-and-forecast-2018-2025

Market segment by Type, the product can be split into
Season
Off-season

Market segment by Application, split into
by car
with the tour

Market segment by Regions/Countries, this report covers
United States
Europe
China
Japan
Southeast Asia
India
Central & South America

The study objectives of this report are:
To analyze global Xian Tourism status, future forecast, growth opportunity, key market and key players.
To present the Xian Tourism development in United States, Europe and China.
To strategically profile the key players and comprehensively analyze their development plan and strategies.
To define, describe and forecast the market by product type, market and key regions.

In this study, the years considered to estimate the market size of Xian Tourism are as follows:
History Year: 2013-2017
Base Year: 2017
Estimated Year: 2018
Forecast Year 2018 to 2025

Leave a Query @ https://www.wiseguyreports.com/enquiry/3431850-global-xian-tourism-market-size-status-and-forecast-2018-2025

Table of Contents

1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered
1.4 Market Analysis by Type
1.4.1 Global Xian Tourism Market Size Growth Rate by Type (2013-2025)
1.4.2 Season
1.4.3 Off-season
1.5 Market by Application
1.5.1 Global Xian Tourism Market Share by Application (2013-2025)
1.5.2 by car
1.5.3 with the tour
1.6 Study Objectives
1.7 Years Considered

2 Global Growth Trends
2.1 Xian Tourism Market Size
2.2 Xian Tourism Growth Trends by Regions
2.2.1 Xian Tourism Market Size by Regions (2013-2025)
2.2.2 Xian Tourism Market Share by Regions (2013-2018)
2.3 Industry Trends
2.3.1 Market Top Trends
2.3.2 Market Drivers
2.3.3 Market Opportunities

….

12 International Players Profiles
12.1 Citadines Centra
12.1.1 Citadines Centra Company Details
12.1.2 Company Description and Business Overview
12.1.3 Xian Tourism Introduction
12.1.4 Citadines Centra Revenue in Xian Tourism Business (2013-2018)
12.1.5 Citadines Centra Recent Development
12.2 Mercure Xi’an on Renmin Square
12.2.1 Mercure Xi’an on Renmin Square Company Details
12.2.2 Company Description and Business Overview
12.2.3 Xian Tourism Introduction
12.2.4 Mercure Xi’an on Renmin Square Revenue in Xian Tourism Business (2013-2018)
12.2.5 Mercure Xi’an on Renmin Square Recent Development
12.3 Chenggong International Hotel
12.3.1 Chenggong International Hotel Company Details
12.3.2 Company Description and Business Overview
12.3.3 Xian Tourism Introduction
12.3.4 Chenggong International Hotel Revenue in Xian Tourism Business (2013-2018)
12.3.5 Chenggong International Hotel Recent Development
12.4 Hilton Xi’an
12.4.1 Hilton Xi’an Company Details
12.4.2 Company Description and Business Overview
12.4.3 Xian Tourism Introduction
12.4.4 Hilton Xi’an Revenue in Xian Tourism Business (2013-2018)
12.4.5 Hilton Xi’an Recent Development
12.5 The Westin Xi’an
12.5.1 The Westin Xi’an Company Details
12.5.2 Company Description and Business Overview
12.5.3 Xian Tourism Introduction
12.5.4 The Westin Xi’an Revenue in Xian Tourism Business (2013-2018)
12.5.5 The Westin Xi’an Recent Development
12.6 Sofitel Xi’an on Renmin Square
12.6.1 Sofitel Xi’an on Renmin Square Company Details
12.6.2 Company Description and Business Overview
12.6.3 Xian Tourism Introduction
12.6.4 Sofitel Xi’an on Renmin Square Revenue in Xian Tourism Business (2013-2018)
12.6.5 Sofitel Xi’an on Renmin Square Recent Development
12.7 Golden Flower Hotel
12.7.1 Golden Flower Hotel Company Details
12.7.2 Company Description and Business Overview
12.7.3 Xian Tourism Introduction
12.7.4 Golden Flower Hotel Revenue in Xian Tourism Business (2013-2018)
12.7.5 Golden Flower Hotel Recent Development
12.8 Grand Park Xi’an
12.8.1 Grand Park Xi’an Company Details
12.8.2 Company Description and Business Overview
12.8.3 Xian Tourism Introduction
12.8.4 Grand Park Xi’an Revenue in Xian Tourism Business (2013-2018)
12.8.5 Grand Park Xi’an Recent Development

13 Market Forecast 2018-2025
13.1 Market Size Forecast by Regions
13.2 United States
13.3 Europe
13.4 China
13.5 Japan
13.6 Southeast Asia
13.7 India
13.8 Central & South America
13.9 Market Size Forecast by Product (2018-2025)
13.10 Market Size Forecast by Application (2018-2025)

Buy Now @ https://www.wiseguyreports.com/checkout?currency=one_user-USD&report_id=3431850

Continued…

Contact Us: Sales@Wiseguyreports.Com Ph: +1-646-845-9349 (Us) Ph: +44 208 133 9349 (Uk)

NORAH TRENT
WISE GUY RESEARCH CONSULTANTS PVT LTD
646-845-9349
email us here


Source: EIN Presswire

Outdoor Leisure Market 2020 Global Share, Trend And Opportunities Forecast To 2025

Wiseguyreports.Com Adds “Outdoor Leisure -Market Demand, Growth, Opportunities and Analysis Of Top Key Player Forecast To 2023” To Its Research Database

PUNE, MAHARASHTRA, INDIA, March 27, 2020 /EINPresswire.com/ — Outdoor Leisure Industry

Description

Outdoor leisure industry is a very lucrative market since engaging in recreational activities can boost confidence levels, enhance creativity and self-esteem. The outdoor industry has grown because it is an affordable option to a healthy lifestyle. The outdoor leisure market has been categorized into inflatable and non-inflatable leisure products. Inflatable products have become increasingly popular over recent years, particularly as advancements in technology have allowed them to become progressively superior to non-inflatables in terms of performance.

The various types of ground and mountain, aerial and water leisure activities offered by different companies are anticipated to grow over the next few years. There has been an increasing participation rate across all age groups for recreational activities specially for water leisure, ranging from young kids to older adults. The growing consumer base has driven a substantial increase in the number and quality of facilitations and locations to engage in water leisure activities and generated strong demand for water leisure products. The vendors are striving to boost comfort levels and developing new products to cater to the needs of growing consumer requirements.

The global outdoor leisure market is set to experience favorable growth driven by factors such as growing youth population, development of tourism industry, increasing popularity of outdoor recreation, plummeting raw material prices and rapid urbanization. The major trends observed in this market include rising penetration in sports & outdoors, launching of new products, emergence of social platforms and growing consumer awareness. However, the growth of this budding market is constrained by challenges such as competition threat, seasonality and low negotiating power of purchasers.

The report “Global Outdoor Leisure Market with Focus on Water Leisure: Industry Analysis & Outlook (2018-2022)” analyses the development of this market, with emphasis on North America, Europe and Asia Pacific markets.

The major trends, growth drivers as well as issues being faced by the market are discussed in detail in this report. The four major players: Bestway Global Holding Inc., Johnson Outdoors Inc., Vista Outdoor Inc. and VF Corporation are being profiled along with their key financials and strategies for growth. The report contains a comprehensive analysis of the global outdoor leisure market along with the study of the regional markets.

Request for Sample Report @ https://www.wiseguyreports.com/sample-request/3431749-global-outdoor-leisure-market-with-focus-on-water

Table of Content

1. Overview

1.1 Outdoor Leisure
1.2 Categories
1.3 Activities

2. Global Market Analysis

2.1 Global Outdoor Leisure Market by Value
2.2 Global Outdoor Leisure Market Forecast by Value
2.3 Global Outdoor Leisure Market by Category
2.3.1 Global Inflatables Products Market by Value
2.3.2 Global Inflatables Products Market Forecast by Value
2.3.3 Global Inflatables Products Market by Category
2.3.4 Global Non-Inflatables Product Market by Value
2.3.5 Global Non-Inflatables Product Market Forecast by Value
2.4 Global Outdoor Leisure Market by Product Type
2.4.1 Global Ground & Mountain Leisure Market by Value
2.4.2 Global Ground & Mountain Leisure Market Forecast by Value
2.4.3 Global Water Leisure Market by Value
2.4.4 Global Water Leisure Market Forecast by Value
2.4.5 Global Water Leisure Market by Category
2.4.6 Global Water Inflatables Product Market by Value
2.4.7 Global Water Inflatables Product Market Forecast by Value
2.4.8 Global Water Non-Inflatables Product Market by Value
2.4.9 Global Water Non-Inflatables Product Market Forecast by Value
2.4.10 Global Aerial Leisure Market by Value
2.4.11 Global Aerial Leisure Market Forecast by Value
2.5 Global Outdoor Leisure Per Capita Consumption by Region
2.6 Global Outdoor Leisure Market by Distribution Channel
2.7 Global Outdoor Leisure Market by Region

3. Regional Market Analysis

3.1 North America
3.1.1 North America Outdoor Leisure Market by Value
3.1.2 North America Outdoor Leisure Market Forecast by Value

3.2 Europe
3.2.1 Europe Outdoor Leisure Market by Value
3.2.2 Europe Outdoor Leisure Market Forecast by Value

3.3 Asia Pacific
3.3.1 Asia Pacific Outdoor Leisure Market by Value
3.3.2 Asia Pacific Outdoor Leisure Market Forecast by Value

3.4 China
3.4.1 China Outdoor Leisure Market by Value
3.4.2 China Outdoor Leisure Market Forecast by Value
3.4.3 China Outdoor Leisure Product Market by Distribution Channel

Leave a Query @ https://www.wiseguyreports.com/enquiry/3431749-global-outdoor-leisure-market-with-focus-on-water

4. Market Dynamics

4.1 Growth Drivers
4.1.1 Increasing Youth Population
4.1.2 Growth in E- Commerce
4.1.3 Development of Tourism Industry
4.1.4 Improving Consumer Confidence Index
4.1.5 Popularity of Outdoor Recreation
4.1.6 Increasing Urban Population
4.1.7 Plummeting Raw Material Prices

4.2 Key Trends & Development
4.2.1 Rising Penetration Rate in Sports & Outdoors
4.2.2 Launching of New Products
4.2.3 Emergence of Social Platforms
4.2.4 Increased Consumer Awareness
4.2.5 Preference for Convenience, Flexibility and Portability
4.2.6 Increased Focus on Health

4.3 Challenges
4.3.1 Competition Threat
4.3.2 Seasonality
4.3.3 Low Negotiating Power of Purchasers

5. Competitive Landscape

5.1 Global Market
5.1.1 Revenue and Market Cap Comparison
5.2 North America
5.2.1 North America Inflatable Outdoor Leisure Market Share by Company
5.2.2 The US Outdoor Leisure Market Share by Company
5.3 Europe
5.3.1 Europe Inflatable Outdoor Leisure Market Share by Company

6. Company Profiles

6.1 Bestway Global Holding Inc.
6.1.1 Business Overview
6.1.2 Financial Overview
6.1.3 Business Strategies

6.2 Johnson Outdoors Inc.
6.2.1 Business Overview
6.2.2 Financial Overview
6.2.3 Business Strategies

6.3 Vista Outdoor Inc.
6.3.1 Business Overview
6.3.2 Financial Overview
6.3.3 Business Strategies

6.4 VF Corporation
6.4.1 Business Overview
6.4.2 Financial Overview
6.4.3 Business Strategies

Buy Now @ https://www.wiseguyreports.com/checkout?currency=one_user-USD&report_id=3431749

Continued…

Contact Us: Sales@Wiseguyreports.Com Ph: +1-646-845-9349 (Us) Ph: +44 208 133 9349 (Uk)

NORAH TRENT
WISE GUY RESEARCH CONSULTANTS PVT LTD
646-845-9349
email us here


Source: EIN Presswire

Hand Sanitizer Market 2020 Industry Key Players, Trends, Sales, Supply, Demand, Analysis & Forecast To 2028

PUNE, MAHARASTRA, INDIA, March 27, 2020 /EINPresswire.com/ — Introduction
Hand Sanitizer Market
Hand Sanitizer market research report provides the newest industry data and industry future trends, allowing you to identify the products and end users driving Revenue growth and profitability.
The industry report lists the leading competitors and provides the insights strategic industry Analysis of the key factors influencing the market.
The report includes the forecasts, Analysis and discussion of important industry trends, market size, market share estimates and profiles of the leading industry Players.

@Get Free Sample Report at https://www.wiseguyreports.com/sample-request/1583952-world-hand-sanitizer-market-research-report-2021

Global Hand Sanitizer Market: Product Segment Analysis
Waterless Hand Sanitizer
Ordinary Hand Sanitizer
Other Hand Sanitizer
Global Hand Sanitizer Market: Application Segment Analysis
Medical
Daily
Other
Global Hand Sanitizer Market: Regional Segment Analysis
USA
Europe
Japan
China
India
South East Asia

Key Players of Global Hand Sanitizer Market =>
• Reckitt Benckiser(UK)
• P&G(US)
• Amway(US)
• 3M(US)
• Lion Corporation(JP)
• Medline(US)
• Vi-Jon(US)
• Henkel(DE)
• Chattem(US)
• Unilever(UK)

With no less than 10 top vendors.

@Enquiry Before Buying https://www.wiseguyreports.com/enquiry/1583952-world-hand-sanitizer-market-research-report-2021

Major Key Points of Global Hand Sanitizer Market
Chapter 1 About the Hand Sanitizer Industry
1.1 Industry Definition and Types
1.1.1 Waterless Hand Sanitizer
1.1.2 Ordinary Hand Sanitizer
1.1.3 Other Hand Sanitizer
1.2 Main Market Activities
1.3 Similar Industries
1.4 Industry at a Glance
…………….
Chapter 5 Company Profiles
5.1 Reckitt Benckiser(UK)
5.1.1 Company Details (Foundation Year, Employee Strength and etc)
5.1.2 Product Information (Picture, Specifications and Applications)
5.1.3 Revenue (M USD), Price and Operating Profits
5.2 P&G(US)
5.2.1 Company Details (Foundation Year, Employee Strength and etc)
5.2.2 Product Information (Picture, Specifications and Applications)
5.2.3 Revenue (M USD), Price and Operating Profits
5.3 Amway(US)
5.3.1 Company Details (Foundation Year, Employee Strength and etc)
5.3.2 Product Information (Picture, Specifications and Applications)
5.3.3 Revenue (M USD), Price and Operating Profits
5.4 3M(US)
5.4.1 Company Details (Foundation Year, Employee Strength and etc)
5.4.2 Product Information (Picture, Specifications and Applications)
5.4.3 Revenue (M USD), Price and Operating Profits
5.5 Lion Corporation(JP)
5.5.1 Company Details (Foundation Year, Employee Strength and etc)
5.5.2 Product Information (Picture, Specifications and Applications)
5.5.3 Revenue (M USD), Price and Operating Profits
5.6 Medline(US)
5.6.1 Company Details (Foundation Year, Employee Strength and etc)
5.6.2 Product Information (Picture, Specifications and Applications)
5.6.3 Revenue (M USD), Price and Operating Profits
5.7 Vi-Jon(US)
5.7.1 Company Details (Foundation Year, Employee Strength and etc)
5.7.2 Product Information (Picture, Specifications and Applications)
5.7.3 Revenue (M USD), Price and Operating Profits
5.8 Henkel(DE)
5.8.1 Company Details (Foundation Year, Employee Strength and etc)
5.8.2 Product Information (Picture, Specifications and Applications)
5.8.3 Revenue (M USD), Price and Operating Profits
5.9 Chattem(US)
5.9.1 Company Details (Foundation Year, Employee Strength and etc)
5.9.2 Product Information (Picture, Specifications and Applications)
5.9.3 Revenue (M USD), Price and Operating Profits
5.10 Unilever(UK)
5.10.1 Company Details (Foundation Year, Employee Strength and etc)
5.10.2 Product Information (Picture, Specifications and Applications)
5.10.3 Revenue (M USD), Price and Operating Profits
5.11 …
5.11.1 Company Details (Foundation Year, Employee Strength and etc)
5.11.2 Product Information (Picture, Specifications and Applications)
5.11.3 Revenue (M USD), Price and Operating Profits
5.12 With no less than 10 top vendors.
5.12.1 Company Details (Foundation Year, Employee Strength and etc)
5.12.2 Product Information (Picture, Specifications and Applications)
5.12.3 Revenue (M USD), Price and Operating Profits

NORAH TRENT
WISE GUY RESEARCH CONSULTANTS PVT LTD
646-845-9349
email us here


Source: EIN Presswire